bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status

Acta Neuropathologica

Volumn 94, Issue 4, 1997, Pages 369-375

  Newcomb, Elizabeth W ^a   Bhalla, Sandhya K ^a   Parrish, Clarissa L ^a   Hayes, Roberta L ^c   Cohen, Henry ^b   Miller, Douglas C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Astrocytomas; bcl 2; p53 tumor suppressor gene; Prognosis; Survival

Indexed keywords

MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE;

EID: 0030803612     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010050721     Document Type: Article

References (38)

1. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW (1995) Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001
2. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77: 255-264
3. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ (1996) Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 148: 1557-1565
4. Chiou S-K, Rao L, White E (1994) bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14: 2556-2563
5. Chozick BS, Weicker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW (1994) Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73: 406-415
6. Deimling A von, Ammon K von, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multi-forme defined by molecular genetic analysis. Brain Pathol 3: 19-26
7. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U (1996) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341-349
8. Ellison DW, Steart PV, Gatter KC, Weller RO (1995) Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361
9. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G (1995) Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003-1007
10. Friesen C, Herr I, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2: 574-577
11. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327
12. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN (1993) Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 16: 93-104
13. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965
14. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumors of the central nervous system. World Health Organization international histological classification of tumors, 2nd edn. Springer, Berlin Heidelberg New York
15. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J (1994) Analysis of p53 gene mutations in low-and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225-232
16. Kordek R, Biernat W, Alwasiak J, Maculewicz R, Yanagihara R, Liberski PP (1995) p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neurooncol 26: 11-16
17. Korsmeyer S (1992) bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886
18. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC (1995) Immunohistochemical analysis of Mcl-1 protein in human tissues. Am J Pathol 146: 1309-1319
19. Krishna M, Smith TW, Recht LD (1995) Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg 83: 1017-1022
20. Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436
21. Lee ET (1980) Statistical methods for survival data analysis. Lifetime Learning Publication, Belmont
22. Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, Cottier H (1993) Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 142: 755-763
23. Meyel DJ van, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG (1994) p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 86: 1011-1017
24. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135
25. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J (1994) bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88: 520-526
26. Oka H, Satoh Y, Kawano N, Yagishita S, Kameya T (1996) Expression of BCL-2 gene product in embryonal tumors of the central nervous system. Surg Neurol 45: 230-235
27. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6
28. Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (1991) Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 51: 6529-6538
29. Rubio M-P, Diemling A von, Yandell DW, Wiestler OD, Gusella JF, Louis DN (1993) Accumulation of wild-type p53 protein in human astrocytomas. Cancer Res 53: 3465-3467
30. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L (1996) Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neurooncol 27: 101-109
31. Siegel S, Castellan NJ Jr (1988) Nonparametric statistics for the behavioral sciences. McGraw-Hill, New York
32. Slooten HJ van, Clahsen PC, Dierendonck JH van, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, Velde CJ van de, Vijver MJ van de (1996) Expression of bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74: 78-85
33. Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, Bergholm U, Coggi G (1995) Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 26: 945-950
34. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutation are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-224
35. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277-284
36. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643
37. Winger MJ, MacDonald DR, Cairncross JG (1989) Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71: 487-493
38. Zar JH (1984) Biostatistical analysis. Prentice-Hall, Engelwood Cliffs